Non-invasive prenatal diagnostics using next generation sequencing: Technical, legal and social challenges

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 6, 2012, Pages 517-528

  Hahn, Sinuhe ^a   Hösli, Irene ^a   Lapaire, Olav ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cell free DNA; Digital PCR; Down syndrome; Next generation sequencing; Non invasive prenatal diagnosis; Patent

Indexed keywords

CYTOSINE; GUANOSINE;

ANEUPLOIDY; BIOINFORMATICS; CELL FREE DNA; CHROMOSOME 21; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; DOWN SYNDROME; FALSE POSITIVE RESULT; FETUS KARYOTYPING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; HIGH RISK PREGNANCY; HUMAN; LEGAL ASPECT; MATERNAL BLOOD; MEDICAL ETHICS; MICROFLUIDICS; NON INVASIVE PRENATAL DIAGNOSIS; PATENT; POLYMERASE CHAIN REACTION; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PROCEDURES CONCERNING CELLS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRISOMY 21;

EID: 84867927349     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.703650     Document Type: Review

References (94)

1. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901
2. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32:3-9
3. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect down syndrome: an international clinical validation study. Genet Med 2011;13:913-20
4. Benn P, Cuckle H, Pergament E. Non-invasive prenatal diagnosis for down syndrome: the paradigm will shift, but slowly. Ultrasound Obstet Gynecol 2012;39:127-30
5. Simpson JL. Is cell-free fetal DNA from maternal blood finally ready for prime time? Obstet Gynecol 2012;119:883-5
6. Liley AW. Amniocentesis. N Engl J Med 1965;272:731-2
7. Liley AW. The technique and complications of amniocentesis. NZ Med J 1960;59:581-6
8. Tabor A, Alfirevic Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 2010;27:1-7
9. Philip J, Silver RK, Wilson RD, et al. Late first-trimester invasive prenatal diagnosis: results of an international randomized trial. Obstet Gynecol 2004;103:1164-73
10. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011;31:7-15
11. Izquierdo LA, Berkshire S. Access, quality and costs of prenatal diagnosis. Bol Asoc Med P R 2010;102:25-9
12. Garrouste C, Le J, Maurin E. The choice of detecting down syndrome: does money matter? Health Econ 2011;20:1073-89
13. Morris JK, Alberman E. Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register. BMJ 2009;339:b3794
14. Hulten MA, Patel S, Jonasson J, et al. On the origin of the maternal age effect in trisomy 21 Down syndrome: the Oocyte Mosaicism Selection model. Reproduction 2010;139:1-9
15. Chiu RW, Lo YM. Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age. Semin Fetal Neonatal Med 2011;16:88-93
16. Bianchi DW. From michael to microarrays: 30 years of studying fetal cells and nucleic acids in maternal blood. Prenat Diagn 2010;30:622-3
17. Hahn S, Jackson LG, et al. Noninvasive prenatal diagnosis of fetal aneuploidies and Mendelian disorders: new innovative strategies. Expert Rev Mol Diagn 2009;9:613-21
18. Bianchi DW. Circulating fetal DNA: its origin and diagnostic potential-a review. Placenta 2004;25(Suppl A):S93-S101
19. Costa JM, Giovangrandi Y, Ernault P, et al. Fetal RHD genotyping in maternal serum during the first trimester of pregnancy. Br J Haematol 2002;119:255-60
20. Devaney SA, Palomaki GE, Scott JA, et al. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011;306:627-36
21. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7
22. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768-75
23. Zimmermann B, El-Sheikhah A, Nicolaides K, et al. Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem 2005;51:1598-604
24. Hill M, Finning K, Martin P, et al. Non-invasive prenatal determination of fetal sex: translating research into clinical practice. Clin Genet 2011;80:68-75
25. van der Schoot CE, Hahn S, Chitty LS. Non-invasive prenatal diagnosis and determination of fetal Rh status. Semin Fetal Neonatal Med 2008;13:63-8
26. Li Y, Di Naro E, Vitucci A, et al. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA 2005;293:843-9
27. Ding C, Chiu RW, Lau TK, et al. MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis. Proc Natl Acad Sci USA 2004;101:10762-7
28. Chiu RW, Cantor CR, Lo YM. Non-invasive prenatal diagnosis by single molecule counting technologies. Trends Genet 2009;25:324-31
29. Hahn S, Jackson LG, Zimmermann BG. Prenatal diagnosis of fetal aneuploidies: post-genomic developments. Genome Med 2010;2:50
30. Choolani M, Ho SS, Razvi K, et al. FastFISH: technique for ultrarapid fluorescence in situ hybridization on uncultured amniocytes yielding results within 2 h of amniocentesis. Mol Hum Reprod 2007;13:355-9
31. Zimmermann B, Holzgreve W, Wenzel F, et al. Novel real-time quantitative PCR test for trisomy 21. Clin Chem 2002;48:362-3
32. Fan HC, Quake SR. Detection of aneuploidy with digital polymerase chain reaction. Anal Chem 2007;79:7576-9
33. Lo YM, Lun FM, Chan KC, et al. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci USA 2007;104:13116-21
34. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA 1999;96:9236-41
35. Zimmermann BG, Grill S, Holzgreve W, et al. Digital PCR: a powerful new tool for noninvasive prenatal diagnosis? Prenat Diagn 2008;28:1087-93
36. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem 2009;55:641-58
37. Voelkerding KV, Lyon E. Digital fetal aneuploidy diagnosis by next-generation sequencing. Clin Chem 2010;56:336-8
38. Fan HC, Blumenfeld YJ, Chitkara U, et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA 2008;105:16266-71
39. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 2008 105:20458-63
40. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401
41. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204:205; e1-11
42. Sehnert AJ, Rhees B, Comstock D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011;57:1042-9
43. Thompson JF, Milos PM. The properties and applications of single-molecule DNA sequencing. Genome Biol 2011;12:217
44. Avent ND. Refining noninvasive prenatal diagnosis with single-molecule next-generation sequencing. Clin Chem 2012;58:657-8
45. van den Oever JM, Balkassmi S, Verweij EJ, et al. Single molecule sequencing of free DNA from maternal plasma for noninvasive trisomy 21 detection. Clin Chem 2012;58:699-706
46. Liao GJ, Lun FM, Zheng YW, et al. Targeted massively parallel sequencing of maternal plasma DNA permits efficient and unbiased detection of fetal alleles. Clin Chem 2011;57:92-101
47. Evans MI, Henry GP, Miller WA, et al. International, collaborative assessment of 146,000 prenatal karyotypes: expected limitations if only chromosome-specific probes and fluorescent in-situ hybridization are used. Hum Reprod 1999;14:1213-16
48. Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14:296-305
49. Stumm M, Entezami M, Trunk N, et al. Noninvasive prenatal detection of chromosomal aneuploidies using different next generation sequencing strategies and algorithms. Prenat Diagn 2012;32:569-77
50. Benn P, Borrell A, Crossley J, et al. Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. Prenat Diagn 2011;31:519-22
51. Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann NY Acad Sci 2004;1022:119-23
52. Szczepura A, Bonsel G, Krauth C, et al. Fetal RHD typing: is fetal RHD typing in all RhD negative women cost effective? BMJ 2008;336:906
53. Daniels G, Finning K, Martin P, Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009;29:101-7
54. Hulten MA, Patel SD, Tankimanova M, et al. On the origin of trisomy 21 down syndrome. Mol Cytogenet 2008;1:21
55. Hulten MA, Patel SD, Westgren M, et al. On the paternal origin of trisomy 21 down syndrome. Mol Cytogenet 2010;3:4
56. Lo YM, Bowell PJ, Selinger M, et al. Prenatal determination of fetal rhesus D status by DNA amplification of peripheral blood of rhesus-negative mothers. Ann NY Acad Sci 1994;731:229-36
57. Lo YM, Patel P, Sampietro M, et al. Detection of single-copy fetal DNA sequence from maternal blood. Lancet 1990;335:1463-4
58. Ganshirt-Ahlert D, Pohlschmidt M, Gal A, et al. Ratio of fetal to maternal DNA is less than 1 in 5000 at different gestational ages in maternal blood. Clin Genet 1990;38:38-43
59. Holzgreve W, Ganshirt-Ahlert D, Burschyk M, et al. Detection of fetal DNA in maternal blood by PCR. Lancet 1990;335:1220-1
60. Stroun M, Maurice P, Vasioukhin V, et al. The origin and mechanism of circulating DNA. Ann NY Acad Sci 2000;906:161-8
61. Cho M. Patently unpatentable: implications of the Myriad court decision on genetic diagnostics. Trends Biotechnol 2010;28:548-51
62. Chitty LS, van der Schoot CE, Hahn S, et al. SAFE-the special non-invasive advances in fetal and neonatal evaluation network: aims and achievements. Prenat Diagn 2008;28:83-8
63. Bianchi DW, Simpson JL, Jackson LG, et al. Fetal cells in maternal blood: NIFTY clinical trial interim analysis. DM-STAT. NICHD fetal cell study (NIFTY) group. Prenat Diagn 1999;19:994-5
64. Lo YM, Hjelm NM, Fidler C, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998;339:1734-8
65. Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184-8
66. Levett LJ, Liddle S, Meredith R. A large-scale evaluation of amnio-PCR for the rapid prenatal diagnosis of fetal trisomy. Ultrasound Obstet Gynecol 2001;17:115-18
67. Greely HT. Get ready for the flood of fetal gene screening. Nature 2011;469:289-91
68. de Jong A, Dondorp WJ, Frints SG, et al. Advances in prenatal screening: the ethical dimension. Nat Rev Genet 2011;12:657-63
69. Barrett AN, Zimmermann BG, Wang D, et al. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One 2011;6:e25202
70. Weatherall D. Thalassemia: the long road from the bedside through the laboratory to the community. Nat Med 2010;16:1112-15
71. Weatherall DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci 2010;1202:17-23
72. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011;118:3479-88
73. Guetta E, Peleg L. Rapid detection of fetal Mendelian disorders: tay-Sachs disease. Methods Mol Biol 2008;444:147-59
74. Dolgin E. Jewish genetic screening grows despite questions about breadth. Nat Med 2011;17:639
75. Rosner G, Rosner S, Orr-Urtreger A. Genetic testing in Israel: an overview. Annu Rev Genomics Hum Genet 2009;10:175-92
76. Remennick L. The quest for the perfect baby: why do Israeli women seek prenatal genetic testing? Sociol Health Illn 2006;28:21-53
77. Cao A. Carrier screening and genetic counselling in beta-thalassemia. Int J Hematol 2002;76:105-13
78. Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010;2:61ra91
79. Ong FS, Grody WW, Deignan JL. Privacy and data management in the era of massively parallel next-generation sequencing. Expert Rev Mol Diagn 2011;11:457-9
80. Lantos JD, Artman M, Kingsmore SF. Ethical considerations associated with clinical use of next-generation sequencing in children. J Pediatr 2011;159:879-80; e1
81. Kitzman JO, Snyder MW, Ventura M, et al. Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med 2012;4:137-76
82. Wilson JL, Ferguson GM, Thorn JM. Genetic testing likelihood: the impact of abortion views and quality of life information on women's decisions. J Genet Couns 2011;20:143-56
83. Pryde PG, Drugan A, Johnson MP, et al. Prenatal diagnosis: choices women make about pursuing testing and acting on abnormal results. Clin Obstet Gynecol 1993;36:469-509
84. Natoli JL, Ackerman DL, McDermott S, et al. Prenat Diagn of down syndrome: a systematic review of termination rates (1995-2011). Prenat Diagn 2012;32:142-53
85. Van Gameren-Oosterom HB, Van Dommelen P, Oudesluys-Murphy AM, et al. Healthy growth in children with down syndrome. PLoS One 2012;7:e31079
86. Skotko BG, Levine SP, Goldstein R. Having a son or daughter with down syndrome: perspectives from mothers and fathers. Am J Med Genet A 2011;155A:2335-47
87. Skotko BG, Levine SP, Goldstein R. Having a brother or sister with down syndrome: perspectives from siblings. Am J Med Genet A 2011;155A:2348-59
88. Kelly SE, Farrimond HR. Non-invasive prenatal genetic testing: a study of public attitudes. Public Health Genomics 2012;15:73-81
89. Bianchi DW. At-home fetal DNA gender testing: caveat emptor. Obstet Gynecol 2006;107:216-18
90. Liotta LA, Petricoin EF. Regulatory approval pathways for molecular diagnostic technology. Methods Mol Biol 2012;823:409-20
91. Liley AW. The foetus as a personality. Aust NZ J Psychiatry 1972;6:99-105
92. Bartesaghi R, Guidi S, Ciani E. Is it possible to improve neurodevelopmental abnormalities in Down syndrome? Rev Neurosci 2011;22:419-55
93. Mattar CN, Choolani M, Biswas A, et al. Fetal gene therapy: recent advances and current challenges. Expert Opin Biol Ther 2011;11:1257-71
94. Lo YM, Chiu RW. Noninvasive approaches to prenatal diagnosis of hemoglobinopathies using fetal DNA in maternal plasma. Hematol Oncol Clin North Am 2010;24:1179-86